Back to Authors

Hao, Yue

https://orcid.org/0000-0002-5065-8906

Mayo Clinic

Translational Genomics Research Institute

Citations 2

Haplotype-resolved genome assemblies of BJ and IMR-90 human fibroblast cell lines reveal extensive structural variation and enable reanalysis of historical sequencing data
Ranallo-Benavidez, T Rhyker, Hao, Yue , Volpe, Emilia, Fukushima, Noelle, Stephens, Zachary, Mbegbu, Ogechukwu, Ungaro, Matteo Tommaso , Reiman, Rebecca, Molnar, Jessica, Murphy, Danyael, Paredes, Dorothy Marie, Wong, Shukmei , Karaniuk, Kara, Buchholtz, Stephanie, Kocher, Jean-Pierre, Keats, Jonathan, Paten, Benedict, Barthel, Floris P, Ranallo-Benavidez, T. Rhyker , Hao, Yue , Ranallo-Benavidez, T Rhyker , Stephens, Zachary D, Kocher, Jean-Pierre A , Paten, Benedict , Barthel, Floris P , Jehangir, Maryam , Fukushima, Noelle H., Paredes, Dorothy Marie, Keats, Jonathan J. , Machiela, Mitchell J. , Kolmogorov, Mikhail , Giunta, Simona

Nucleic Acids Research | April 29, 2026 | Volume: 54 | Issue: 8 | Pages: No page available

10.1093/nar/gkag333 Get It

Abstract We present chromosome-level, phased diploid genome assemblies of two widely used human fibroblast cell lines: BJ (46,XY) and IMR-90 (46,XX). Using Oxford Nanopore, PacBio HiFi, and Hi-C sequencing data, we generated assemblies spanning 5.9 and 6.0 Gbp with diploid quality values exceeding QV 60. To validate structural integrity, we developed KaryoScope, an alignment-free tool for generating computational karyograms from k-mer feature databases. We identify >50 000 structural variants relative to T2T-CHM13v2.0, the majority of which are heterozygous and cell-line-specific. Combining reference-based and de novo gene annotation, we uncover a previously unreported 1 Mbp homozygous duplication at the 16p11.2 locus in BJ, demonstrating that even karyotypically normal cell lines can harbor clinically relevant submicroscopic rearrangements. We show that mapping publicly available short-read, RNA-seq, and ChIP-seq data to sample-matched diploid assemblies substantially improves read alignment and enables haplotype phasing of 23%–28% of short reads. The BJ and IMR-90 assemblies and associated variant calls are publicly available as a resource for the research community.
Androgen loss weakens anti-tumor immunity and accelerates brain tumor growth 3761
Silver, Daniel J. , Swanson, Kristin R. , Sharifi, Nima , Lathia, Justin D. , Swanson, Kristin R , Lee, Juyeun , Chung, Yoon‐Mi , Hao, Yue , Curtin, Lee , Nicosia, Michael , Berens, Michael E.

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1526 Get It

Abstract Description Many cancers, including glioblastoma (GBM), exhibit a male-biased incidence and outcome disparity, partially driven by sex hormones. While androgens are known to suppress anti-tumor T cell immunity in certain solid tumors, we found that androgens instead enhance anti-tumor immunity in brain tumors. Upon castration, tumor growth was accelerated in brain tumor models, while the opposite effect was observed for tumors located outside the brain. Decreased T cell function was observed in both tumors and peripheral lymphoid organs in castrated mice, indicated by reduced anti-tumor cytokines and increased T cell exhaustion. Mechanistically, this systemic immunosuppression was driven by hyperactivation of the hypothalamus-pituitary-adrenal (HPA) axis in castrated mice with brain tumors. Blocking glucocorticoid receptors reversed the accelerated tumor growth in these mice, confirming the role of HPA axis dysregulation. This mechanism was brain-specific rather than GBM-specific, as hyperactivation of the HPA axis was also observed with intracranial implantation of non-GBM tumors. Furthermore, elevated production of proinflammatory cytokines (IL-1β, TNF) in the brain of castrated mice was identified as a driver of HPA axis activation. Taken together, these findings reveal unique endocrine-mediated mechanisms by which brain tumor modulate systemic immunity in the androgen-deprived setting and highlight the importance of organ-specific effects of anti-tumor immunity. Funding Sources NIH P01CA245705; NIH R35NS127083; American Brain Tumor Association; Cleveland Clinic; Case comprehensive cancer center Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)